Healthcare Business of Merck

Name

Healthcare Business of Merck

Legal name

Merck KGaA, Darmstadt, Germany

Website

https://merckgroup.com

Company type

Public

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Merck KGaA's Healthcare Business develops and markets pharmaceutical therapies across oncology, neurology, immunology, fertility, endocrinology, and rare tumors. Operating in the US and Canada under the EMD Serono brand, it serves patients, hospitals, and providers via global pharmaceutical sales and distribution networks.

Ownership category

akta.pro rank

Product category

Pharmaceutical Healthcare

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Oncology Specialty Pharmaceuticals (HLAIACAA)

akta.pro secondary industries

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA), Specialty Care Pharmaceuticals (HLAIAAAB)

Keywords

• Pharmaceutical therapies
• Oncology treatments
• Fertility treatments
• Neurology immunology
• Rare tumor therapies

Headquarters

HQ city

Darmstadt

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Revenue model

1. Healthcare Products and Services: Revenue generated from pharmaceutical products, therapies, vaccines, and healthcare solutions across therapeutic areas including oncology, neurology & immunology, fertility, and general medicine

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

The Healthcare business of Merck KGaA, Darmstadt, Germany develops, manufactures, and commercializes pharmaceutical therapies and drugs across multiple therapeutic areas including oncology, neurology & immunology, fertility, cardiovascular/metabolism/endocrinology, and rare tumors. The business serves patients through healthcare providers, hospitals, clinics, and pharmaceutical distributors across more than 65 countries.

Differentiator

Problem solved

Functional benefit

Products and services

• Oncology

Segments5 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature3 records

Partnerships

Two partnerships are on record, tiered strategic.

• LenovostrategicTechnology or Integration · 1 January 2025Collaboration to successfully launch a state-of-the-art high-performance computer in Munich, Germany. This partnership combines Lenovo's technology capabilities with Merck's infrastructure needs.
• EquinixstrategicTechnology or Integration · 1 January 2025Collaboration to successfully launch a state-of-the-art high-performance computer in Munich, Germany. Equinix provides data center infrastructure for the high-performance computing solution.

Scale indicators2 records

Direct peers

• Roche: Swiss global pharmaceutical company with leading oncology and neurology franchises. Highly comparable to Merck KGaA Healthcare in therapeutic area focus (oncology, neurology, immunology) and enterprise sales model to hospitals and specialists.
• AbbVie: Specialty pharmaceutical company with strong immunology, oncology, and neuroscience franchises. Closely comparable innovator-pharma business model and overlapping therapeutic areas with Merck KGaA Healthcare.
• Sanofi: European-headquartered global pharmaceutical company with specialty care, immunology, neurology, and rare disease franchises. Directly comparable in therapeutic mix and geographic footprint to Merck KGaA Healthcare.
• GSK: UK-headquartered global pharmaceutical company with specialty medicines, vaccines, and immunology. Comparable breadth of therapeutic areas and enterprise go-to-market, with overlap in vaccines/immunology and oncology.
• Bristol-Myers Squibb: Specialty pharmaceutical company with concentrated oncology and immunology franchises. Comparable innovator-pharma model and similar therapeutic area overlap with Merck KGaA Healthcare.
• AstraZeneca: Global oncology-led pharmaceutical company with growing rare disease, cardiovascular, and immunology portfolios. Highly comparable on oncology pipeline depth and enterprise healthcare-provider go-to-market.
• Eli Lilly: Global pharmaceutical company with leading endocrinology, oncology, and neurology franchises. Directly comparable on the endocrinology/metabolism segment and growing oncology pipeline.
• Bayer: German-headquartered peer with pharmaceutical division covering women's health/fertility, cardiology, and oncology. Closest home-market comparable to Merck KGaA Healthcare with overlapping fertility and cardiovascular franchises.
• Novartis: Swiss specialty pharmaceutical company with major oncology, neurology, and immunology franchises. Comparable therapeutic breadth and innovator-pharma business model overlapping with Merck KGaA Healthcare's primary segments.

Broad incumbents

• Pfizer: Largest US-headquartered pharmaceutical company with oncology, vaccines, neurology, and rare disease franchises. Operates in overlapping therapeutic areas but at much greater scale and across a broader portfolio than Merck KGaA Healthcare.

Market position

Customer concentration

• Xtwitter.com/merck_group
• Facebookfacebook.com/MerckKGaA
• LinkedInlinkedin.com/company/merck-group
• Instagraminstagram.com/merckkgaa

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Healthcare Business of Merck